axl bemcentinib Search Results


94
Selleck Chemicals bemcentinib
Medium components used in the BBB studies
Bemcentinib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/axl+bemcentinib/Bemcentinib/pmc11000354-93-0-10
Average 94 stars, based on 1 article reviews
bemcentinib - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
MedChemExpress axl kinase inhibitor r428
Medium components used in the BBB studies
Axl Kinase Inhibitor R428, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/axl+bemcentinib/Bemcentinib/pmc07015993__mmc1-147-0-7
Average 96 stars, based on 1 article reviews
axl kinase inhibitor r428 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

90
BerGenBio bemcentinib axl
Selected studies of TAM receptor inhibitors combined with CPI therapies in CPI-resistant NSCLC
Bemcentinib Axl, supplied by BerGenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/axl+bemcentinib/bgb324/pmc09305809-5-0-3
Average 90 stars, based on 1 article reviews
bemcentinib axl - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BerGenBio axl inhibitor bemcentinib r428
Selected studies of TAM receptor inhibitors combined with CPI therapies in CPI-resistant NSCLC
Axl Inhibitor Bemcentinib R428, supplied by BerGenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/axl+bemcentinib/r428/pmc12205699-691-3-17
Average 90 stars, based on 1 article reviews
axl inhibitor bemcentinib r428 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
TargetMol axl inhibitor bemcentinib
Selected studies of TAM receptor inhibitors combined with CPI therapies in CPI-resistant NSCLC
Axl Inhibitor Bemcentinib, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/axl+bemcentinib/Cytokine+Inhibitor+Library/pm42260511-199-10-13
Average 95 stars, based on 1 article reviews
axl inhibitor bemcentinib - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

90
BerGenBio axl inhibitor bemcentinib
Selected studies of TAM receptor inhibitors combined with CPI therapies in CPI-resistant NSCLC
Axl Inhibitor Bemcentinib, supplied by BerGenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/axl+bemcentinib/axl+kinase+inhibitor/pm33586501-139-71-70
Average 90 stars, based on 1 article reviews
axl inhibitor bemcentinib - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Medium components used in the BBB studies

Journal: Fluids and Barriers of the CNS

Article Title: SARS-CoV-2 causes dysfunction in human iPSC-derived brain microvascular endothelial cells potentially by modulating the Wnt signaling pathway

doi: 10.1186/s12987-024-00533-9

Figure Lengend Snippet: Medium components used in the BBB studies

Article Snippet: Bemcentinib (#S2841, AXL inhibitor) and CHIR99021 (#S1263) were obtained from Selleck Chemicals (Houston, TX, USA).

Techniques: Concentration Assay, Solvent

SARS-CoV-2 receptor for infection examined in human iPSC-BMELCs. A Expression of SARS-CoV-2 receptor candidates was determined by RT-qPCR. B Cells were treated with ACE2 Ab (20 μg/mL), Meplazumab (20 μg/mL), Bemcentinib (1 μM), or EG00229 (100 μM) 1 h before SARS-CoV-2 infection (MOI = 1). The intracellular viral copy number was determined by RT-qPCR. Normalized value of SARS-CoV-2 RNA copies was indicated against vehicle control as 100%. Data are represented as mean ± SD (n = 3)

Journal: Fluids and Barriers of the CNS

Article Title: SARS-CoV-2 causes dysfunction in human iPSC-derived brain microvascular endothelial cells potentially by modulating the Wnt signaling pathway

doi: 10.1186/s12987-024-00533-9

Figure Lengend Snippet: SARS-CoV-2 receptor for infection examined in human iPSC-BMELCs. A Expression of SARS-CoV-2 receptor candidates was determined by RT-qPCR. B Cells were treated with ACE2 Ab (20 μg/mL), Meplazumab (20 μg/mL), Bemcentinib (1 μM), or EG00229 (100 μM) 1 h before SARS-CoV-2 infection (MOI = 1). The intracellular viral copy number was determined by RT-qPCR. Normalized value of SARS-CoV-2 RNA copies was indicated against vehicle control as 100%. Data are represented as mean ± SD (n = 3)

Article Snippet: Bemcentinib (#S2841, AXL inhibitor) and CHIR99021 (#S1263) were obtained from Selleck Chemicals (Houston, TX, USA).

Techniques: Infection, Expressing, Quantitative RT-PCR, Control

Selected studies of TAM receptor inhibitors combined with CPI therapies in CPI-resistant NSCLC

Journal: Journal for Immunotherapy of Cancer

Article Title: Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

doi: 10.1136/jitc-2022-004863

Figure Lengend Snippet: Selected studies of TAM receptor inhibitors combined with CPI therapies in CPI-resistant NSCLC

Article Snippet: Bemcentinib Axl , BerGenBio/ Merck Sharp & Dohme , NCT03184571 , 2 , 09/2022 , 106† , Bemcentinib + pembrolizumab After a median treatment duration of 8.9 weeks, among CPI-refractory pts (Cohort B) with cAxl-positive tumors (n=7): ORR: 14% (1 pt with PR) CBR: 86% (6 pts) mPFS: 4.73 mo (HR 0.22; 95% CI 0.04 to 1.26; p=0.066) .

Techniques: